Role of ICH guidelines in registration of Pharmaceutical Products
The International Conference on Harmonization (ICH) of Technical Requirements is a unique project for Registration of Pharmaceutical products which are intended for human use. This brings together the regulatory authorities of Europe, Japan and United States and experts from the pharmaceutical industry in the three regions to discuss scientific and technical aspects of product registration.
The purpose is to make recommendations on ways to achieve greater harmonization in the interpretation and application of technical guidelines and requirements for product registration in order to reduce or obviate the need to duplicate the testing carried out during the research and development of new medicines.
The objective of such harmonization is a more economical use of human, animal and material resources and the elimination of unnecessary delay in the global development and availability of new medicines whilst maintaining safeguards on quality, safety and efficacy and regulatory obligations to protect public health. It creates a venue that allows all key pharmaceutical regulatory authorities and industry stakeholders the opportunity to be more actively involved in pharmaceutical harmonization work. It aimed at the standardization of requirements and format along with the content of regulatory documentation and brings down the pressure on the price of medicines by enabling greater economies of scale and a labelled regulatory playing field. This paper is an effort to provide the detailed information about ICH Guidelines.
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/idelines/Quality/Q8_9_10_QAs/Pt C /Quality_IWG_PtCR2_6dec2011.pdf
2. MedDRA [Internet]. Meddra; 2019 [cited, 2019 Sept 02]. Available from: http://www.meddra.org
3. Bitragunta S, Suresh PV et al. Chalapathi Institute of Pharmaceutical Sciences, pharmatutor.org.art-1205.
4. Van der Laan, Willem J; DeGeorge, Joseph. Global Approach in Safety Testing: ICH Guidelines Explained. 2013; p.1-23.
5. Somvanshi et al. ICH guidelines and main focus on stability guidelines for new formulation and dosage forms. WJPR. 2015; 4(10): 561-78.
6. Pokharana. M, Vaishnav R, Goyal A, Shrivastava A. Stability testing guidelines of Pharmaceutical Products; Journal of drug delivery and therapeutics. 2018; 8(2):169-75.
7. ICH Q1A (R2). Stability testing guidelines: Stability testing of new drug substances and products. ICH Steering Committee [Internet]. London: EMEA; 2003 [cited 2019 Sept 30]. Available from:
8. Welankiwar. A et al.; Photostability testing of pharmaceutical products. Int. Res. J. Pharm. 2013; 4(9):11-15
9. Somvanshi et al. ICH guidelines. World Journal of Pharmaceutical Research. 2015; 4(10):561-78.
10. Yadav. C et al. Aspects of Pharmaceutical Process Validation: A Review. IJPPR. 2018; 14(1):55-66.
11. Validation of Analytical Procedures: Text and Methodology Q2(R1), ICH Harmonised Tripartite guidelines, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2005.
12. Ravisankar P, Navya CN et al. A Review on Step-by-Step Analytical Method Validation. IOSR Journal of Pharmacy. [Internet]. Iosrphr; 2015 Oct [cited 2019 Sept 14]; 5(10):7-19. Available from:
13. Romanach. R.J, Paternia A.S. “Theory of sampling in Pharmaceutical manufacturing”. Impublications. com. 2015; (5): 67-70.
14. VK Chaudhari, V Yadav, et al. A Review on Good Manufacturing Practice (GMP) for Medicinal products. Pharma Tutor. 2014; 2(9): 8-19.
15. Shukla. A, Vishnoi. G, et al.; Current Good Manufacturing Guidelines for Medicinal product. Journal of Drug Delivery and Therapeutics. 2016; 6(2): 57-61.
16. Pharmacopoeia [Internet]. Wikipedia; 2018. [cited 2019 Sept 15]. Available from:
17. Soni N. Specifications for Starting Materials, Intermediates and Finished Products. PharmaTutor. 2016; 4(11):21-26.
18. Geigert J. The Center for Professional Innovation and Education (CfPIE) [Internet]. CfPIE; 2019 [cited 2019 Sept 15]. Available from:
19. Jena et al. Regulatory requirements and ICH Guidelines on Carcinogeneticity testing of pharmaceuticals- A review on current status. Indian Journal of Pharmacology. 2005 Aug; 37(4):209-22.
20. Reddenna L, Venkatesh P, Kumar KS, Reddy ASK. Genotoxicity. PharmaTutor. 2017; 5(9):23-34
21. ICH guideline S2 (R1) on genotoxicity testing and data interpretation for pharmaceuticals intended for human use EMA/CHMP/ICH/126642/2008 [Internet]. London: EMEA; 2008 [cited 2019 Sept 22]. Available from:
https://www.ema.europa.eu › documents › scientific-guideline
22. Note for guidance on Toxicokinetics: A guidance for assessing systemic exposure in Toxicology studies (CPMP/ICH/384/95) [Internet]. EMEA[cited 2019 Sept 17]. Available from:
https://www.ema.europa.eu › documents › scientific-guideline.
23. ICH Topic S3B Pharmacokinetics: Repeated Dose Tissue Distribution Studies (CPMP/ICH/385/95) [Internet]. London:EMEA; 1995[cited 2019 Sept 17]. Available from:
24. Reproductive toxicity [Internet]. Wikipedia;2019 [cited 2019 Sept 17]. Available from:
25. Preclinical safety evaluation of biotechnology-derived pharmaceuticals EMA/CHMP/ICH/731268; 1998.
26. Terry P. Kenakin. Safety Pharmacology, Pharmacology in Drug Discovery and Development .2nd Edition; 2017. P. 251-73.
27. International Conference in Harmonisation. Harmonised Tripartite Guideline: Immunotoxicity Studies for Human Pharmaceuticals S8. [Internet]. ICH; 2005 [cited 2019 Sept 13]. Available from:
28. Kawabata TT, Evans EW. ‘Development of Immunotoxicity Testing Strategies for Immunomodulatory Drugs. 2012; 40(2): 288-93.
29. S10 Photosafety Evaluation of Pharmaceuticals Guidance for Industry [Internet]. US:FDA [cited 2019 Sept 13]. Available from:
30. 3T3 Cells [Internet]. Wikipedia [cited 2019 Sept 13]. Available from:
https://en.wikipedia.org › wiki › 3T3_cells.
31. Suke SG, Kosta P, et al. Role of Pharmacovigilance in India: An overview. Online Journal of Public Health Information. 2015; 7(2): e223.
32. Arora.R, et al. Pharmacovigilance: A way for better tomorrow, International Research Journal of Pharmacy. 2011; 2(12):43-6.
33. Bridging study [Internet]. [cited 2019 Sept 11]. Available from:
https://ww2.amstat.org›fdaworkshop›presentations › P3_Chow_Bridging
34. ICH harmonised guideline integrated addendum to ICH E6(R1): Guideline for Good Clinical Practice ICH E6(R2) ICH Consensus Guideline [Internet]. FDA; 2018Mar [cited 2019 Sept 12]. Available from:
35. E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1) Guidance for Industry [Internet]. FDA; 2018 [cited 2019 Sept 15]. Available from:
36. Guideline on good pharmacovigilance practices (GVP) – P. IV EMA/572054/2016 [Internet]. EMEA; 2018. [cited 2019 Sept 18]. Available from:
https://www.ema.europa.eu › documents › scientific-guideline › guideline
37. ICH M1 PtC EWG/IWG Work Plan January 18, 2019. [Internet]. ICH; 2019 Jan 18. [cited 2019 Sept 19]. Available from:
38. Singh S, Kumar P, Rana A. Global Regulatory challenges of common technical document. Wjpps. 2017; 6(12):1298-309.
39. M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals [Internet]. GMP Compliance [cited 2019 Sept 19]. Available from:
40. Sama R, et al. Electronic Common Technical document (eCTD). IJPCBS. 2016; 6(2):133-49.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM